Preclinical studies with erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - Elsevier
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
[引用][C] Preclinical studies with erlotinib (Tarceva)
RW AKITA, MX SLIWKOWSKI - Seminars in oncology, 2003 - pascal-francis.inist.fr
Preclinical studies with erlotinib (Tarceva) CNRS Inist Pascal-Francis CNRS Pascal and
Francis Bibliographic Databases Simple search Advanced search Search by classification …
Francis Bibliographic Databases Simple search Advanced search Search by classification …
Preclinical studies with Erlotinib (Tarceva).
RW Akita, MX Sliwkowski - Seminars in Oncology, 2003 - europepmc.org
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Preclinical studies with Erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in Oncology, 2003 - infona.pl
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
[引用][C] Preclinical studies with Erlotinib (Tarceva)
R AKITA, M SLIWKOWSKI - Seminars in Oncology, 2003 - cir.nii.ac.jp
Preclinical studies with Erlotinib (Tarceva) | CiNii Research CiNii 国立情報学研究所 学術情報
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす …
ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学図書館の本をさがす …
Preclinical studies with Erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in oncology, 2003 - pubmed.ncbi.nlm.nih.gov
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
Preclinical studies with Erlotinib (Tarceva)
RW Akita, MX Sliwkowski - Seminars in Oncology, 2003 - infona.pl
Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available,
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …
highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) …